Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System
COPENHAGEN, Denmark, April 24, 2024 /PRNewswire/ -- Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies' pipeline candidates. The joint invention aims to revolutionize transdermal release of "difficult-to-formulate" compounds targeting the endocannabinoid system.
- The collaboration brings together Tetra Pharm Technologies' expertise in enabling technology with Glysious' proprietary transdermal drug delivery system, renowned for its effectiveness, comfort, and convenience.
- COPENHAGEN, Denmark, April 24, 2024 /PRNewswire/ -- Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies' pipeline candidates.
- Back in 2023 Glysious and Tetra Pharm Technologies performed early in-vitro feasibility tests, integrating Tetra Pharma Technologies' proprietary enabling technology for delivery of poorly soluble compounds with Glysious' patch.
- Martin Rose, Chief Executive Officer, Tetra Pharm Technologies, concludes: "The collaboration represents a unique opportunity to harness the synergies between our respective technologies.